Failure of recombinant factor VIIa in a patient with severe polymicrobial sepsis and postoperative uncontrolled intraabdominal bleeding

被引:4
作者
Conen, Anna [1 ]
Weisser, Maja
Tsakiris, Dimitrios A.
Siegemund, Martin
机构
[1] Univ Basel Hosp, Dept Infect Dis, CH-4031 Basel, Switzerland
[2] Univ Basel Hosp, Med Intens Care Unit, CH-4031 Basel, Switzerland
[3] Univ Basel Hosp, Div Haematol, CH-4031 Basel, Switzerland
[4] Univ Basel Hosp, Dept Anaesthesia & Intens Care Med, CH-4031 Basel, Switzerland
关键词
D O I
10.1186/1471-2334-7-34
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: This report discusses a case of unsuccessful treatment with recombinant factor VIIa ( rFVIIa) in off-label use. The need for international guidelines concerning the off-label use of rFVIIa is outlined as well as the need for methods to control the efficacy of rFVIIa objectively. Case presentation: 54 year old male with severe polymicrobial sepsis due to a perforated diverticulitis of the sigmoid colon and consecutive overt disseminated intravascular coagulation. He suffered severe intraabdominal bleeding after abdominal surgery despite conventional haemostatic support. Repeated applications of factor VIIa temporarily improved coagulation essays but did not stop clinical bleeding. The patient died in multiorgan failure due to septic and haemorrhagic shock. Conclusion: Off-label use of rFVIIa could result in more side effects than could be expected from literature because of a publication bias. However for most off-label applications large prospective, randomised and controlled trials to confirm the positive findings are missing. For the future, not only guidelines concerning the off-label use of rFVIIa are urgently needed but also guidelines for monitoring the efficacy of rFVIIa.
引用
收藏
页数:6
相关论文
共 23 条
[1]   Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: Two parallel randomized, placebo-controlled, double-blind clinical trials [J].
Boffard, KD ;
Riou, B ;
Warren, B ;
Choong, PIT ;
Rizoli, S ;
Rossaint, R ;
Axelsen, M ;
Kluger, Y .
JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE, 2005, 59 (01) :8-16
[2]   'Last-ditch' use of recombinant factor VIIa in patients with massive haemorrhage is ineffective [J].
Clark, AD ;
Gordon, WC ;
Walker, ID ;
Tait, RC .
VOX SANGUINIS, 2004, 86 (02) :120-124
[3]   Ineffective off-label use of recombinant activated factor VII in a case of bone-marrow transplantation-related gastrointestinal bleeding [J].
Eller P. ;
Pechlaner C. ;
Wiedermann C.J. .
Thrombosis Journal, 4 (1)
[4]   Off-license use of recombinant activated factor VII [J].
Ghorashian, S ;
Hunt, BJ .
BLOOD REVIEWS, 2004, 18 (04) :245-259
[5]  
Hedner U, 1996, HAEMOSTASIS, V26, P102
[6]  
Hedner U, 1990, Blood Coagul Fibrinolysis, V1, P307, DOI 10.1097/00001721-199008000-00009
[7]  
HEDNER U, 1988, LANCET, V2, P1193
[8]   Disseminated intravascular coagulation: What's new? [J].
Levi, M .
CRITICAL CARE CLINICS, 2005, 21 (03) :449-+
[9]   Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding:: A systematic review [J].
Levi, M ;
Peters, M ;
Büller, HR .
CRITICAL CARE MEDICINE, 2005, 33 (04) :883-890
[10]   USE OF RECOMBINANT ACTIVATED FACTOR-VII FOR TREATMENT OF A RETROPHARYNGEAL HEMORRHAGE IN A HEMOPHILIC PATIENT WITH A HIGH TITER INHIBITOR [J].
MACIK, BG ;
HOHNEKER, J ;
ROBERTS, HR ;
GRIFFIN, AM .
AMERICAN JOURNAL OF HEMATOLOGY, 1989, 32 (03) :232-234